in the absence of a submission from the holder of the marketing authorisation:

naltrexone / bupropion (Mysimba®) is not recommended for use within NHSScotland.

Indication under review: As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of
• ≥ 30 kg/m² (obese), or
• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download full details192KB (PDF)


Medicine details

Medicine name:
naltrexone bupropion (Mysimba)
Pharmaceutical company
Orexigen Therapeutics Ireland Limited (1)
BNF chapter
Submission type
Non submission
Not recommended
Date advice published:
07 May 2018